{"id":"vorapaxar-and-clopidogrel","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding"},{"rate":"2-5","effect":"Dyspnea"},{"rate":"1-3","effect":"Bradycardia"},{"rate":"1-3","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist that blocks thrombin-induced platelet activation, while clopidogrel is a P2Y12 receptor antagonist that inhibits ADP-mediated platelet aggregation. Together, they provide complementary antiplatelet effects to reduce thrombotic cardiovascular events.","oneSentence":"Vorapaxar and clopidogrel work together as dual antiplatelet agents to prevent blood clots by blocking platelet activation and aggregation through different pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:54.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Secondary prevention of atherothrombotic events in patients with stable coronary artery disease"}]},"trialDetails":[{"nctId":"NCT03207451","phase":"PHASE4","title":"Vorapaxar on Thrombin Generation and Coagulability","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2016-01-01","conditions":"Coronary Artery Disease, Peripheral Vascular Disease, Myocardial Infarction","enrollment":81},{"nctId":"NCT02548650","phase":"PHASE4","title":"Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-03-25","conditions":"Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease","enrollment":66},{"nctId":"NCT00684203","phase":"PHASE2","title":"Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-01","conditions":"Atherosclerosis, Myocardial Ischemia, Myocardial Infarction","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group 2"],"phase":"marketed","status":"active","brandName":"Vorapaxar and Clopidogrel","genericName":"Vorapaxar and Clopidogrel","companyName":"Inova Health Care Services","companyId":"inova-health-care-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vorapaxar and clopidogrel work together as dual antiplatelet agents to prevent blood clots by blocking platelet activation and aggregation through different pathways. Used for Acute coronary syndrome, Secondary prevention of atherothrombotic events in patients with stable coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}